FindTrial
Sign In

A prospective clinical study of modified biological valve aortic root replacement to reduce the risk of coronary artery occlusion after long-term biological valve decay and transcatheter middle aortic valve replacement

A prospective clinical study of modified biological valve aortic root replacement to reduce the risk of coronary artery occlusion after long-term biological valve decay and transcatheter middle aortic valve replacement

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300073512
Enrollment
Unknown
Registered
2023-07-13
Start date
2022-07-28
Completion date
Unknown
Last updated
2023-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

aortic root aneurysm with aortic valve disease

Interventions

Experimental group:Modified Bio-Bentall

Sponsors

Fuwai Hospital, Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with aortic root aneurysm and aortic valve disease who are going to undergo biological valve Bentall in our department, including patients with simple biological valve Bentall or combined with other operations. Aged >=50 years old, regardless of gender.

Exclusion criteria

Exclusion criteria: Bentall bioprosthesis combined with coronary artery bypass grafting.

Design outcomes

Secondary

MeasureTime frame
hospital mortality;The incidence of complications such as secondary thoracotomy hemostasis and perioperative myocardial infarction;—

Primary

MeasureTime frame
Coronary risk of TAVR after Bentall operation;—

Countries

China

Contacts

Public ContactHu Xiaopeng

Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

13621188439@139.com+86 136 2118 8439

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026